신장암 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Kidney Cancer Drugs Market size is expected to reach USD 12.65 Billion in 2034 from USD 7.47 Billion (2025) growing at a CAGR of 6.02% during 2026-2034.

The Global Kidney Cancer Drugs Market is experiencing steady growth due to the increasing prevalence of renal cell carcinoma and the rising demand for effective oncology treatments. Kidney cancer remains one of the most commonly diagnosed cancers worldwide, and advancements in targeted therapies and immunotherapies are significantly improving treatment outcomes. Growing awareness regarding early cancer detection and improved access to advanced healthcare facilities are also contributing to the expansion of this market.

Pharmaceutical companies are investing heavily in research and development to introduce innovative therapies that offer improved survival rates and reduced side effects. Targeted drugs and immune checkpoint inhibitors are becoming increasingly popular as they provide more precise treatment options for kidney cancer patients. Additionally, the expansion of clinical trials and regulatory approvals for novel drugs is supporting market growth across various regions.

Looking ahead, the Global Kidney Cancer Drugs Market is expected to witness substantial expansion due to continued advancements in cancer research and personalized medicine. Biotechnology companies are exploring new drug combinations and immunotherapy approaches to improve treatment effectiveness. With increasing healthcare spending and growing emphasis on oncology care, the market for kidney cancer drugs is projected to grow significantly in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Cancer Type

• Renal Cell Carcinoma (RCC)
• Transitional Cell Cancer
• Wilms Tumor
• Renal Sarcoma

By Therapy

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Other Therapies

By Drug Class

• Angiogenesis Inhibitors
• Monoclonal Antibodies
• mTOR Inhibitors
• Cytokine Immunotherapy (IL-2)
• Other Drug Classes

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By Distribution Channel

• Hospital Pharmacy
• Brick and Mortar
• E-commerce

COMPANIES PROFILED

• Active Biotech AB, Amgen Inc, Astellas Pharma Inc, AstraZeneca PLC, Bayer AG, BristolMyers Squibb Company, Eisai Co Ltd, Exelixis Inc, F HoffmannLa Roche Ltd, Genentech Inc, GSK plc, Helsinn Healthcare SA, Johnson Johnson Services Inc, Merck Co Inc, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL KIDNEY CANCER DRUGS MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Cancer Type
• 4.2. Renal Cell Carcinoma (RCC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Transitional Cell Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Wilms Tumor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Renal Sarcoma Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL KIDNEY CANCER DRUGS MARKET: BY THERAPY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy
• 5.2. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL KIDNEY CANCER DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Class
• 6.2. Angiogenesis Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. mTOR Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cytokine Immunotherapy (IL-2) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL KIDNEY CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL KIDNEY CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Brick and Mortar Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. E-commerce Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL KIDNEY CANCER DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Cancer Type
  • 9.2.2 By Therapy
  • 9.2.3 By Drug Class
  • 9.2.4 By Route Of Administration
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Cancer Type
  • 9.3.2 By Therapy
  • 9.3.3 By Drug Class
  • 9.3.4 By Route Of Administration
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Cancer Type
  • 9.4.2 By Therapy
  • 9.4.3 By Drug Class
  • 9.4.4 By Route Of Administration
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Cancer Type
  • 9.5.2 By Therapy
  • 9.5.3 By Drug Class
  • 9.5.4 By Route Of Administration
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Cancer Type
  • 9.6.2 By Therapy
  • 9.6.3 By Drug Class
  • 9.6.4 By Route Of Administration
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL KIDNEY CANCER DRUGS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Active Biotech AB
  • 11.2.2 Amgen Inc
  • 11.2.3 Astellas Pharma Inc
  • 11.2.4 AstraZeneca PLC
  • 11.2.5 Bayer AG
  • 11.2.6 Bristol-Myers Squibb Company
  • 11.2.7 Eisai Co. Ltd
  • 11.2.8 Exelixis Inc
  • 11.2.9 F. Hoffmann-La Roche Ltd
  • 11.2.10 Genentech Inc
  • 11.2.11 GSK Plc
  • 11.2.12 Helsinn Healthcare SA
  • 11.2.13 Johnson & Johnson Services Inc
  • 11.2.14 Merck & Co. Inc
  • 11.2.15 Novartis AG